Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 757Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 447Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 184Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

urelumab 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × B-Cell Malignancies × Clear all
NCT05683717 2023-11-21

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

TransThera Sciences (Nanjing), Inc.

Phase 1 Recruiting
37 enrolled
Lymphoid

B-Cell Malignancies

NCT05275504 2022-06-09

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

TransThera Sciences (Nanjing), Inc.

Phase 1 Unknown
37 enrolled
Lymphoid

B-Cell Malignancies

NCT01775631 2017-03-31

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
47 enrolled
Lymphoid

B-Cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡